NAVIGATOR also showed activity in heavily pretreated KIT-mutant GIST, particularly in tumors with activation loop mutations, although dose-dependent neurocognitive adverse events were observed, informing subsequent dose-modification strategies and clinical management recommendations [158]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.